It is with great pleasure that we announce that our CEO, Gloria Seibert, has been featured in a detailed article in the renowned Frankfurter Allgemeine Zeitung. The contribution sheds light on her impressive career and the groundbreaking innovations she has accomplished with Temedica in the field of health insights.
With her unique vision, Gloria Seibert has made Temedica a pioneer in the digital health industry. The article illustrates how, with innovative solutions and a holistic approach to healthcare, she has been able to convince prominent investors and experts. With Temedica, Gloria has created a collaborative ecosystem in which all stakeholders – from patients and life sciences companies to researchers, HCPs, and health insurance companies – work together to realize personalized healthcare.
From the humble beginnings in a small office space to today's central role in the European health sector, the development of Temedica and Gloria Seibert's innovative vision is traced. It is particularly emphasized how Temedica has revolutionized the world of health data by analyzing billions of data points related to thousands of different medical conditions to enable individualized treatment methods and more efficient clinical trials.
We are incredibly proud of Gloria's achievements and her relentless commitment. Her vision of personalized medicine and her ambition to make health insights accessible are a daily inspiration to all of us.
You can find the complete article “The Data Manager of Medicine” here. Please note that the article is written in German.
About Temedica
Temedica is a health insights company based in Munich. Since 2016, Temedica has been operating Europe's leading ecosystem for real world insights in the healthcare sector. Temedica's mission is to enable personalized and individualized medicine, thereby focusing on patients and their individual needs. The company achieves this by linking health-related data from various sources, which are processed into valuable insights in compliance with the GDPR.
Temedica is backed by a consortium of renowned investors with many years of experience in the biopharmaceutical industry, including the founding investors of BioNTech. For further information, please visit https://temedica.com/.
For more information, please contact:
Temedica GmbH
Anna Hauner
Corporate Communications
Phone: +49 (0) 175 4310301
Mail: pr@temedica.com